FDA's Antiviral Drugs Advisory Committee
Executive Summary
Panel will meet July 28, not on July 29 as had been previously scheduled, to discuss Burroughs Wellcome's Retrovir (zidovudine) "for prophylaxis against maternal to fetal transmission of HIV infection." The dates were shuffled when a review of the OTC switch application for Zovirax was postponed ("The Pink Sheet" July 4, T&G-10)